Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Capstone Therapeutics (CAPS) Presents at Rodman & Renshaw Conference

Capstone Therapeutics Corp. (OTC: CAPS) is a biotechnology company committed to developing a pipeline of novel peptides and other molecules aimed at helping patients with underserved medical conditions. Its primary asset is ownership in a joint-venture development company, LipimetiX Development, Inc., based in Natick, Massachusetts.  In 2012, Capstone invested $6 million in the joint venture for 60% ownership. Its partners in the venture include three PhD drug developers, The University of Alabama at Birmingham Research Foundation and scientists at The University of Alabama at Birmingham. For more information, visit the company’s website at www.capstonethx.com.

Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory, and related services to public and private companies across multiple sectors and regions. Rodman also provides research and sales and trading services to institutional investors. For more information on Rodman & Renshaw, visit www.rodmanandrenshaw.com.
This entry was posted in Rodman and Renshaw Conference. Bookmark the permalink.

Comments are closed.